Assessment of sexual function in postmenopausal breast cancer survivors.

Autor:	Vitorino CN; Graduate Program in Obstetrics and Gynecology, Medical School, São Paulo State University, Botucatu, São Paulo 18618-970, Brazil., Omodei MS; Graduate Program in Obstetrics and Gynecology, Medical School, São Paulo State University, Botucatu, São Paulo 18618-970, Brazil., de Souza RC; Graduate Program in Obstetrics and Gynecology, Medical School, São Paulo State University, Botucatu, São Paulo 18618-970, Brazil., Nahas GP; Department of Obstetrics and Gynecology, Medical School, São Paulo State University, Botucatu, São Paulo 18618-970, Brazil., de Araujo Brito Buttros D; Graduate Program in Obstetrics and Gynecology, Medical School, São Paulo State University, Botucatu, São Paulo 18618-970, Brazil., Carvalho-Pessoa E; Graduate Program in Obstetrics and Gynecology, Medical School, São Paulo State University, Botucatu, São Paulo 18618-970, Brazil.; Department of Obstetrics and Gynecology, Medical School, São Paulo State University, Botucatu, São Paulo 18618-970, Brazil., Vespoli HL; Graduate Program in Obstetrics and Gynecology, Medical School, São Paulo State University, Botucatu, São Paulo 18618-970, Brazil.; Department of Obstetrics and Gynecology, Medical School, São Paulo State University, Botucatu, São Paulo 18618-970, Brazil., Nahas EAP; Graduate Program in Obstetrics and Gynecology, Medical School, São Paulo State University, Botucatu, São Paulo 18618-970, Brazil.; Department of Obstetrics and Gynecology, Medical School, São Paulo State University, Botucatu, São Paulo 18618-970, Brazil.
Jazyk:	angličtina
Zdroj:	Sexual medicine [Sex Med] 2024 Jun 28; Vol. 12 (3), pp. qfae035. Date of Electronic Publication: 2024 Jun 28 (Print Publication: 2024).
DOI:	10.1093/sexmed/qfae035
Abstrakt:	Background: Breast cancer (BC) is considered a risk factor for sexual dysfunction, which may be associated with the diagnosis itself or with oncological treatments. However, sexual dysfunction often remains underdiagnosed and unaddressed among BC survivors. Aim: The study sought to evaluate the sexual function of postmenopausal BC survivors compared with postmenopausal women without BC. Methods: This case-control study included 178 postmenopausal BC survivors (stages I-III), 45 to 70 years of age, with amenorrhea for ≥12 months and sexually active. They were compared with 178 women without BC, matched (±2 years) for age and time since menopause in a 1:1 ratio. Sexual function was evaluated using the Female Sexual Function Index (FSFI), which consists of 6 domains (desire, arousal, lubrication, orgasm, satisfaction, and pain), with a total score ≤26.5 indicating risk of sexual dysfunction. Statistical analysis included Student's t test, chi-square test, and logistic regression (odds ratio [OR]). Outcomes: Evaluation of sexual function in postmenopausal women treated for BC. Results: Postmenopausal BC survivors showed poorer sexual function in the desire domain ( P = .002). No significant differences were observed between groups in the other FSFI domains and total score ( P >  .05). Postmenopausal BC survivors had a higher prevalence of risk of sexual dysfunction (64.6% with a total score ≤26.5) compared with the control group (51.6%) ( P = .010). Adjusted risk analysis for age and time since menopause revealed a higher risk of sexual dysfunction in BC survivors compared with women without cancer (OR, 1.98; 95% confidence interval, 1.29-2.96; P = .007). Among BC survivors, the use of hormone therapy was associated with a higher risk of sexual dysfunction (OR, 3.46; 95% confidence interval, 1.59-7.51; P = .002). Clinical Implications: Postmenopausal BC survivors should be regularly assessed before and throughout treatment to enable the early detection and diagnosis of sexual dysfunction. Strength and Limitations: The main strength is that this study might contribute to a better understanding of sexual function in postmenopausal BC survivors compared with women without BC. The main limitation is that while the FSFI is a valid and reliable tool for the evaluation of female sexual function, it does not allow a comprehensive diagnosis of sexual dysfunction, as it is not applicable to partners. Conclusion: Compared with postmenopausal women without BC, postmenopausal BC survivors face a higher risk of sexual dysfunction, especially when treated with adjuvant hormone therapy. Competing Interests: The authors declare no conflict of interest. (© The Author(s) 2024. Published by Oxford University Press on behalf of The International Society of Sexual Medicine.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu